bluuebunny/crossref_metadata_2025 huggingface dataset:
Females display relatively preserved muscle quality compared with males during the onset and early stages of C26-induced cancer cachexia
Authors: Cabrera Ana Regina , Deaver J. William , Lim Seongkyun , Morena da Silva Francielly , Schrems Eleanor R. , Saling Landen W. , Tsitkanou Stavroula , Rosa-Caldwell Megan E. , Wiggs Michael P. , Washington Tyrone A. , Greene Nicholas P.
Published: August 2023

Our study demonstrates biological-sex differences in phenotypic characteristics of cancer cachexia between male and female mice, whereby females display many common characteristics of cachexia (gonadal fat loss and hepatosplenomegaly), protein synthesis markers alterations, and common catabolic markers in skeletal muscle despite relatively preserved muscle mass in early-stage cachexia compared with males. Mechanisms of cancer cachexia appear to differ between sexes. Data suggest need to place onus of early cancer cachexia detection and treatment on nonmuscle tissues in females.
Supplementary Figures and Tables 1 from Treatment Response in First-Line Metastatic Pancreatic Ductal Adenocarcinoma Is Stratified By a Composite Index of Tumor Proliferation and CD8 T-Cell Infiltration
Authors: Beatty Gregory L. , Delman Devora , Yu Jiayi , Liu Mingen , Li Joey H. , Zhang Liti , Lee Jae W. , Chang Renee B. , Bahary Nathan , Kennedy Eugene P. , Wang-Gillam Andrea , Rossi Gabriela R. , Garrido-Laguna Ignacio
Published: August 2023

Supplementary Figures 1-5 and Supplementary Tables 1-2
Supplementary Data 2 from Treatment Response in First-Line Metastatic Pancreatic Ductal Adenocarcinoma Is Stratified By a Composite Index of Tumor Proliferation and CD8 T-Cell Infiltration
Authors: Beatty Gregory L. , Delman Devora , Yu Jiayi , Liu Mingen , Li Joey H. , Zhang Liti , Lee Jae W. , Chang Renee B. , Bahary Nathan , Kennedy Eugene P. , Wang-Gillam Andrea , Rossi Gabriela R. , Garrido-Laguna Ignacio
Published: August 2023

DEG Table for R vs NR (mRNAseq)
Supplementary Data 1 from Treatment Response in First-Line Metastatic Pancreatic Ductal Adenocarcinoma Is Stratified By a Composite Index of Tumor Proliferation and CD8 T-Cell Infiltration
Authors: Beatty Gregory L. , Delman Devora , Yu Jiayi , Liu Mingen , Li Joey H. , Zhang Liti , Lee Jae W. , Chang Renee B. , Bahary Nathan , Kennedy Eugene P. , Wang-Gillam Andrea , Rossi Gabriela R. , Garrido-Laguna Ignacio
Published: August 2023

DEG Table for Pre vs Post (mRNAseq)
Data from Treatment Response in First-Line Metastatic Pancreatic Ductal Adenocarcinoma Is Stratified By a Composite Index of Tumor Proliferation and CD8 T-Cell Infiltration
Authors: Beatty Gregory L. , Delman Devora , Yu Jiayi , Liu Mingen , Li Joey H. , Zhang Liti , Lee Jae W. , Chang Renee B. , Bahary Nathan , Kennedy Eugene P. , Wang-Gillam Andrea , Rossi Gabriela R. , Garrido-Laguna Ignacio
Published: August 2023

AbstractPurpose:
Determinants of treatment outcomes to chemotherapy-based regimens in metastatic pancreatic ductal adenocarcinoma (PDA) remain ill-defined. Our aim was to examine tissue-based correlates of treatment response and resistance using matched baseline and on-treatment biopsies collected from patients with PDA treated in the first-line metastatic setting.
Experimental Design:
Patients with treatment-naïve metastatic PDA were enrolled in a Phase II trial (NCT02077881) investigating gemcitabine plus nab-paclitaxel in combination with indoximod, an orally administered small-molecule inhibitor of the IDO pathway. Baseline and on-treatment biopsies (week 8) of metastatic lesions (88% liver) were collected from a cohort of responders (N = 8) and non-responders (N = 8) based on RECIST v1.1 and examined by multiplex IHC and mRNA sequencing.
Results:
Treatment altered the transcriptional profile of metastatic lesions with a decrease in tumor cell proliferation independent of treatment response. The antiproliferative response was seen in both basal and classical PDA subtypes. PDA subtype was not associated with survival outcomes; instead, genes involved in immune activation distinguished responders from non-responders. Tumor response was associated with an increase in CD3+ and CD8+ T-cell infiltrates into metastatic lesions. A composite of decreased tumor proliferation in response to treatment and increased CD8 T-cell infiltration in metastatic lesions identified responders and associated with a favorable survival outcome.
Conclusions:
Our findings suggest that inhibiting cancer cell proliferation alone in PDA is insufficient to produce tumor responses and support a role for tumor-extrinsic mechanisms, such as CD8+ T cells, which combine with the cancer cell proliferation index to define treatment outcomes.
Urinary Tumor DNA MRD Analysis to Identify Responders to Neoadjuvant Immunotherapy in Muscle-invasive Bladder Cancer
Authors: Zhang Ruiyun , Zang Jingyu , Jin Di , Xie Feng , Shahatiaili Akezhouli , Wu Guangyu , Zhang Lu , Wang Lu , Zhang Yue , Zhao Zhixin , Du Pan , Jia Shidong , Fan Jinhai , Zhuang Guanglei , Chen Haige
Published: August 2023

Purpose:

Bladder preservation is a viable option for some patients with muscle-invasive bladder cancer (MIBC), but an effective noninvasive biomarker test to accurately identify promising candidates is lacking. Here we present the clinical application of a novel tissue-agnostic, urine-based minimal residual disease (MRD) assay in the neoadjuvant setting for personalized disease surveillance and actionable target identification to facilitate bladder-sparing treatment approaches.

Patients and Methods:

The urinary tumor DNA (utDNA) analysis was evaluated in an investigator-initiated phase I trial RJBLC-I2N003 in which 20 patients diagnosed with resectable MIBC were treated presurgically with the PD-1 inhibitor toripalimab followed by radical cystectomy (RC).

Results:

We showed that neoadjuvant toripalimab therapy was feasible, safe, and induced a 40% rate (8/20) of pathologic complete response. Longitudinal utDNA profiling outperformed radiographic assessment and conventional biomarkers to predict the pathologic outcome of immune checkpoint blockade. In addition to detecting 3 exceptional responders with molecular MRD-negative status, we identified 7 other individuals characterized for utDNA response and 4 harboring FGFR3 mutants, all of whom (60%, 12/20) could have postponed or avoided RC.

Conclusions:

These findings demonstrate the safety and efficacy of neoadjuvant toripalimab, and suggest the immense potential of noninvasive utDNA MRD testing to guide tailored decision-making with regard to bladder preservation and change the current treatment paradigm for patients with MIBC.
Supplementary Tables from Small Molecule Inhibitors of TEAD Auto-palmitoylation Selectively Inhibit Proliferation and Tumor Growth of NF2-deficient Mesothelioma
Authors: Tang Tracy T. , Konradi Andrei W. , Feng Ying , Peng Xiao , Ma Mingyue , Li Jian , Yu Fa-Xing , Guan Kun-Liang , Post Leonard
Published: August 2023

Supplementary Tables
Supplementary Data from Small Molecule Inhibitors of TEAD Auto-palmitoylation Selectively Inhibit Proliferation and Tumor Growth of NF2-deficient Mesothelioma
Authors: Tang Tracy T. , Konradi Andrei W. , Feng Ying , Peng Xiao , Ma Mingyue , Li Jian , Yu Fa-Xing , Guan Kun-Liang , Post Leonard
Published: August 2023

Supplementary Materials and Methods, Supplementary Figures and Figure Legends
Supplementary Figures from Targeting Upregulated cIAP2 in SOX10-Deficient Drug Tolerant Melanoma
Authors: Glasheen McKenna Q. , Caksa Signe , Young Amelia G. , Wilski Nicole A. , Ott Connor A. , Chervoneva Inna , Flaherty Keith T. , Herlyn Meenhard , Xu Xiaowei , Aplin Andrew E. , Capparelli Claudia
Published: August 2023

Supplementary Figures 1-4
Supplementary Data from Targeting Upregulated cIAP2 in SOX10-Deficient Drug Tolerant Melanoma
Authors: Glasheen McKenna Q. , Caksa Signe , Young Amelia G. , Wilski Nicole A. , Ott Connor A. , Chervoneva Inna , Flaherty Keith T. , Herlyn Meenhard , Xu Xiaowei , Aplin Andrew E. , Capparelli Claudia
Published: August 2023

Full size western blots
Data from Targeting Upregulated cIAP2 in SOX10-Deficient Drug Tolerant Melanoma
Authors: Glasheen McKenna Q. , Caksa Signe , Young Amelia G. , Wilski Nicole A. , Ott Connor A. , Chervoneva Inna , Flaherty Keith T. , Herlyn Meenhard , Xu Xiaowei , Aplin Andrew E. , Capparelli Claudia
Published: August 2023

Abstract
Drug tolerance and minimal residual disease (MRD) are likely to prelude acquired resistance to targeted therapy. Mechanisms that allow persister cells to survive in the presence of targeted therapy are being characterized but selective vulnerabilities for these subpopulations remain uncertain. We identified cellular inhibitor of apoptosis protein 2 (cIAP2) as being highly expressed in SOX10-deficient drug tolerant persister (DTP) melanoma cells. Here, we show that cIAP2 is sufficient to induce tolerance to MEK inhibitors, likely by decreasing the levels of cell death. Mechanistically, cIAP2 is upregulated at the transcript level in SOX10-deficient cells and the AP-1 complex protein, JUND, is required for its expression. Using a patient-derived xenograft model, we demonstrate that treatment with the cIAP1/2 inhibitor, birinapant, during the MRD phase delays the onset of resistance to BRAF inhibitor and MEK inhibitor combination therapy. Together, our data suggest that cIAP2 upregulation in SOX10-deficient subpopulations of melanoma cells induces drug tolerance to MAPK targeting agents and provides a rationale to test a novel therapeutical approach to target MRD.
Table S3 from CD69 Imposes Tumor-Specific CD8+ T-cell Fate in Tumor-Draining Lymph Nodes
Authors: Koyama-Nasu Ryo , Kimura Motoko Y. , Kiuchi Masahiro , Aoki Ami , Wang Yangsong , Mita Yukiyoshi , Hasegawa Ichita , Endo Yukihiro , Onodera Atsushi , Hirahara Kiyoshi , Motohashi Shinichiro , Nakayama Toshinori
Published: August 2023

Table S3
Table S2 from CD69 Imposes Tumor-Specific CD8+ T-cell Fate in Tumor-Draining Lymph Nodes
Authors: Koyama-Nasu Ryo , Kimura Motoko Y. , Kiuchi Masahiro , Aoki Ami , Wang Yangsong , Mita Yukiyoshi , Hasegawa Ichita , Endo Yukihiro , Onodera Atsushi , Hirahara Kiyoshi , Motohashi Shinichiro , Nakayama Toshinori
Published: August 2023

Table S2
Table S1 from CD69 Imposes Tumor-Specific CD8+ T-cell Fate in Tumor-Draining Lymph Nodes
Authors: Koyama-Nasu Ryo , Kimura Motoko Y. , Kiuchi Masahiro , Aoki Ami , Wang Yangsong , Mita Yukiyoshi , Hasegawa Ichita , Endo Yukihiro , Onodera Atsushi , Hirahara Kiyoshi , Motohashi Shinichiro , Nakayama Toshinori
Published: August 2023

Table S1
Supplementary Figure 6 from Granulocyte–Macrophage Colony-Stimulating Factor Influence on Soluble and Membrane-Bound ICOS in Combination with Immune Checkpoint Blockade
Authors: Li Xiaoyu , Li Jingjing , Zheng Yue , Lee Sandra J. , Zhou Jun , Giobbie-Hurder Anita , Butterfield Lisa H. , Dranoff Glenn , Hodi F. Stephen
Published: August 2023

Supplementary figure 6
Supplementary Table S9 from Immunogenetic Metabolomics Reveals Key Enzymes That Modulate CAR T-cell Metabolism and Function
Authors: Renauer Paul , Park Jonathan J. , Bai Meizhu , Acosta Arianny , Lee Won-Ho , Lin Guang Han , Zhang Yueqi , Dai Xiaoyun , Wang Guangchuan , Errami Youssef , Wu Terence , Clark Paul , Ye Lupeng , Yang Quanjun , Chen Sidi
Published: August 2023

Supplementary Table S9
Supplementary Figure 2 from Granulocyte–Macrophage Colony-Stimulating Factor Influence on Soluble and Membrane-Bound ICOS in Combination with Immune Checkpoint Blockade
Authors: Li Xiaoyu , Li Jingjing , Zheng Yue , Lee Sandra J. , Zhou Jun , Giobbie-Hurder Anita , Butterfield Lisa H. , Dranoff Glenn , Hodi F. Stephen
Published: August 2023

Supplementary figure 2
Supplementary Table S8 from Immunogenetic Metabolomics Reveals Key Enzymes That Modulate CAR T-cell Metabolism and Function
Authors: Renauer Paul , Park Jonathan J. , Bai Meizhu , Acosta Arianny , Lee Won-Ho , Lin Guang Han , Zhang Yueqi , Dai Xiaoyun , Wang Guangchuan , Errami Youssef , Wu Terence , Clark Paul , Ye Lupeng , Yang Quanjun , Chen Sidi
Published: August 2023

Supplementary Table S8
Supplementary Figure 1 from Granulocyte–Macrophage Colony-Stimulating Factor Influence on Soluble and Membrane-Bound ICOS in Combination with Immune Checkpoint Blockade
Authors: Li Xiaoyu , Li Jingjing , Zheng Yue , Lee Sandra J. , Zhou Jun , Giobbie-Hurder Anita , Butterfield Lisa H. , Dranoff Glenn , Hodi F. Stephen
Published: August 2023

Supplementary Figure 1
Supplementary Table S7 from Immunogenetic Metabolomics Reveals Key Enzymes That Modulate CAR T-cell Metabolism and Function
Authors: Renauer Paul , Park Jonathan J. , Bai Meizhu , Acosta Arianny , Lee Won-Ho , Lin Guang Han , Zhang Yueqi , Dai Xiaoyun , Wang Guangchuan , Errami Youssef , Wu Terence , Clark Paul , Ye Lupeng , Yang Quanjun , Chen Sidi
Published: August 2023

Supplementary Table S7
Supplementary Table 3 from Systemic Alterations in Type-2 Conventional Dendritic Cells Lead to Impaired Tumor Immunity in Pancreatic Cancer
Authors: James C. Alston , Baer John M. , Zou Chong , Panni Usman Y. , Knolhoff Brett L. , Hogg Graham D. , Kingston Natalie L. , Kang Liang-I. , Lander Varintra E. , Luo Jingqin , Tao Yu , Watson Mark A. , Aft Rebecca , Fields Ryan C. , Hawkins William G. , DeNardo David G.
Published: August 2023

Supplementary Table 3
Supplementary Table S6 from Immunogenetic Metabolomics Reveals Key Enzymes That Modulate CAR T-cell Metabolism and Function
Authors: Renauer Paul , Park Jonathan J. , Bai Meizhu , Acosta Arianny , Lee Won-Ho , Lin Guang Han , Zhang Yueqi , Dai Xiaoyun , Wang Guangchuan , Errami Youssef , Wu Terence , Clark Paul , Ye Lupeng , Yang Quanjun , Chen Sidi
Published: August 2023

Supplementary Table S6
Supplementary Table S5 from Immunogenetic Metabolomics Reveals Key Enzymes That Modulate CAR T-cell Metabolism and Function
Authors: Renauer Paul , Park Jonathan J. , Bai Meizhu , Acosta Arianny , Lee Won-Ho , Lin Guang Han , Zhang Yueqi , Dai Xiaoyun , Wang Guangchuan , Errami Youssef , Wu Terence , Clark Paul , Ye Lupeng , Yang Quanjun , Chen Sidi
Published: August 2023

Supplementary Table S5
Supplementary Table S2 from Immunogenetic Metabolomics Reveals Key Enzymes That Modulate CAR T-cell Metabolism and Function
Authors: Renauer Paul , Park Jonathan J. , Bai Meizhu , Acosta Arianny , Lee Won-Ho , Lin Guang Han , Zhang Yueqi , Dai Xiaoyun , Wang Guangchuan , Errami Youssef , Wu Terence , Clark Paul , Ye Lupeng , Yang Quanjun , Chen Sidi
Published: August 2023

Supplementary Table S2
Supplementary Table S1 from Immunogenetic Metabolomics Reveals Key Enzymes That Modulate CAR T-cell Metabolism and Function
Authors: Renauer Paul , Park Jonathan J. , Bai Meizhu , Acosta Arianny , Lee Won-Ho , Lin Guang Han , Zhang Yueqi , Dai Xiaoyun , Wang Guangchuan , Errami Youssef , Wu Terence , Clark Paul , Ye Lupeng , Yang Quanjun , Chen Sidi
Published: August 2023

Supplementary Table S1
Table S3 from Circulating and Intratumoral Immune Determinants of Response to Atezolizumab plus Bevacizumab in Patients with Variant Histology or Sarcomatoid Renal Cell Carcinoma
Authors: Saliby Renee Maria , El Zarif Talal , Bakouny Ziad , Shah Valisha , Xie Wanling , Flippot Ronan , Denize Thomas , Kane M. Harry , Madsen Katrine N. , Ficial Miriam , Hirsch Laure , Wei Xiao X. , Steinharter John A. , Harshman Lauren C. , Vaishampayan Ulka N. , Severgnini Mariano , McDermott David F. , Lee Gwo-Shu Mary , Xu Wenxin , Van Allen Eliezer M. , McGregor Bradley A. , Signoretti Sabina , Choueiri Toni K. , McKay Rana R. , Braun David A.
Published: August 2023

Supplementary table 3
Supplementary Data from Circulating and Intratumoral Immune Determinants of Response to Atezolizumab plus Bevacizumab in Patients with Variant Histology or Sarcomatoid Renal Cell Carcinoma
Authors: Saliby Renee Maria , El Zarif Talal , Bakouny Ziad , Shah Valisha , Xie Wanling , Flippot Ronan , Denize Thomas , Kane M. Harry , Madsen Katrine N. , Ficial Miriam , Hirsch Laure , Wei Xiao X. , Steinharter John A. , Harshman Lauren C. , Vaishampayan Ulka N. , Severgnini Mariano , McDermott David F. , Lee Gwo-Shu Mary , Xu Wenxin , Van Allen Eliezer M. , McGregor Bradley A. , Signoretti Sabina , Choueiri Toni K. , McKay Rana R. , Braun David A.
Published: August 2023

Titles and captions of supplementary figures
Table S1 from β-Catenin Drives Butyrophilin-like Molecule Loss and γδ T-cell Exclusion in Colon Cancer
Authors: Suzuki Toshiyasu , Kilbey Anna , Casa-Rodríguez Nuria , Lawlor Amy , Georgakopoulou Anastasia , Hayman Hannah , Yin Swe Kyi Lai , Nordin Anna , Cantù Claudio , Vantourout Pierre , Ridgway Rachel A. , Byrne Ryan M. , Chen Lei , Verzi Michael P. , Gay David M. , Gil Vázquez Ester , Belnoue-Davis Hayley L. , Gilroy Kathryn , Køstner Anne Helene , Kersten Christian , Thuwajit Chanitra , Andersen Ditte K. , Wiesheu Robert , Jandke Anett , Blyth Karen , Roseweir Antonia K. , Leedham Simon J. , Dunne Philip D. , Edwards Joanne , Hayday Adrian , Sansom Owen J. , Coffelt Seth B.
Published: August 2023

Clinicopathological characteristics of colon cancer patient cohorts.
Figure S9 from Circulating and Intratumoral Immune Determinants of Response to Atezolizumab plus Bevacizumab in Patients with Variant Histology or Sarcomatoid Renal Cell Carcinoma
Authors: Saliby Renee Maria , El Zarif Talal , Bakouny Ziad , Shah Valisha , Xie Wanling , Flippot Ronan , Denize Thomas , Kane M. Harry , Madsen Katrine N. , Ficial Miriam , Hirsch Laure , Wei Xiao X. , Steinharter John A. , Harshman Lauren C. , Vaishampayan Ulka N. , Severgnini Mariano , McDermott David F. , Lee Gwo-Shu Mary , Xu Wenxin , Van Allen Eliezer M. , McGregor Bradley A. , Signoretti Sabina , Choueiri Toni K. , McKay Rana R. , Braun David A.
Published: August 2023

Supplementary Figure 9
Supplementary Figure Legends from β-Catenin Drives Butyrophilin-like Molecule Loss and γδ T-cell Exclusion in Colon Cancer
Authors: Suzuki Toshiyasu , Kilbey Anna , Casa-Rodríguez Nuria , Lawlor Amy , Georgakopoulou Anastasia , Hayman Hannah , Yin Swe Kyi Lai , Nordin Anna , Cantù Claudio , Vantourout Pierre , Ridgway Rachel A. , Byrne Ryan M. , Chen Lei , Verzi Michael P. , Gay David M. , Gil Vázquez Ester , Belnoue-Davis Hayley L. , Gilroy Kathryn , Køstner Anne Helene , Kersten Christian , Thuwajit Chanitra , Andersen Ditte K. , Wiesheu Robert , Jandke Anett , Blyth Karen , Roseweir Antonia K. , Leedham Simon J. , Dunne Philip D. , Edwards Joanne , Hayday Adrian , Sansom Owen J. , Coffelt Seth B.
Published: August 2023

Supplementary Figure Legends
Figure S8 from Circulating and Intratumoral Immune Determinants of Response to Atezolizumab plus Bevacizumab in Patients with Variant Histology or Sarcomatoid Renal Cell Carcinoma
Authors: Saliby Renee Maria , El Zarif Talal , Bakouny Ziad , Shah Valisha , Xie Wanling , Flippot Ronan , Denize Thomas , Kane M. Harry , Madsen Katrine N. , Ficial Miriam , Hirsch Laure , Wei Xiao X. , Steinharter John A. , Harshman Lauren C. , Vaishampayan Ulka N. , Severgnini Mariano , McDermott David F. , Lee Gwo-Shu Mary , Xu Wenxin , Van Allen Eliezer M. , McGregor Bradley A. , Signoretti Sabina , Choueiri Toni K. , McKay Rana R. , Braun David A.
Published: August 2023

Supplementary Figure 8
Figure S7 from β-Catenin Drives Butyrophilin-like Molecule Loss and γδ T-cell Exclusion in Colon Cancer
Authors: Suzuki Toshiyasu , Kilbey Anna , Casa-Rodríguez Nuria , Lawlor Amy , Georgakopoulou Anastasia , Hayman Hannah , Yin Swe Kyi Lai , Nordin Anna , Cantù Claudio , Vantourout Pierre , Ridgway Rachel A. , Byrne Ryan M. , Chen Lei , Verzi Michael P. , Gay David M. , Gil Vázquez Ester , Belnoue-Davis Hayley L. , Gilroy Kathryn , Køstner Anne Helene , Kersten Christian , Thuwajit Chanitra , Andersen Ditte K. , Wiesheu Robert , Jandke Anett , Blyth Karen , Roseweir Antonia K. , Leedham Simon J. , Dunne Philip D. , Edwards Joanne , Hayday Adrian , Sansom Owen J. , Coffelt Seth B.
Published: August 2023

Impact of Btnl1 and Btnl6 expression on Vgamma7+ cells and the tumor microenvironment
Figure S6 from β-Catenin Drives Butyrophilin-like Molecule Loss and γδ T-cell Exclusion in Colon Cancer
Authors: Suzuki Toshiyasu , Kilbey Anna , Casa-Rodríguez Nuria , Lawlor Amy , Georgakopoulou Anastasia , Hayman Hannah , Yin Swe Kyi Lai , Nordin Anna , Cantù Claudio , Vantourout Pierre , Ridgway Rachel A. , Byrne Ryan M. , Chen Lei , Verzi Michael P. , Gay David M. , Gil Vázquez Ester , Belnoue-Davis Hayley L. , Gilroy Kathryn , Køstner Anne Helene , Kersten Christian , Thuwajit Chanitra , Andersen Ditte K. , Wiesheu Robert , Jandke Anett , Blyth Karen , Roseweir Antonia K. , Leedham Simon J. , Dunne Philip D. , Edwards Joanne , Hayday Adrian , Sansom Owen J. , Coffelt Seth B.
Published: August 2023

Identification of a WNT responsive element (WRE) in the HNF4G genomic locus.
Figure S6 from Circulating and Intratumoral Immune Determinants of Response to Atezolizumab plus Bevacizumab in Patients with Variant Histology or Sarcomatoid Renal Cell Carcinoma
Authors: Saliby Renee Maria , El Zarif Talal , Bakouny Ziad , Shah Valisha , Xie Wanling , Flippot Ronan , Denize Thomas , Kane M. Harry , Madsen Katrine N. , Ficial Miriam , Hirsch Laure , Wei Xiao X. , Steinharter John A. , Harshman Lauren C. , Vaishampayan Ulka N. , Severgnini Mariano , McDermott David F. , Lee Gwo-Shu Mary , Xu Wenxin , Van Allen Eliezer M. , McGregor Bradley A. , Signoretti Sabina , Choueiri Toni K. , McKay Rana R. , Braun David A.
Published: August 2023

Supplementary Figure 6
Figure S4 from β-Catenin Drives Butyrophilin-like Molecule Loss and γδ T-cell Exclusion in Colon Cancer
Authors: Suzuki Toshiyasu , Kilbey Anna , Casa-Rodríguez Nuria , Lawlor Amy , Georgakopoulou Anastasia , Hayman Hannah , Yin Swe Kyi Lai , Nordin Anna , Cantù Claudio , Vantourout Pierre , Ridgway Rachel A. , Byrne Ryan M. , Chen Lei , Verzi Michael P. , Gay David M. , Gil Vázquez Ester , Belnoue-Davis Hayley L. , Gilroy Kathryn , Køstner Anne Helene , Kersten Christian , Thuwajit Chanitra , Andersen Ditte K. , Wiesheu Robert , Jandke Anett , Blyth Karen , Roseweir Antonia K. , Leedham Simon J. , Dunne Philip D. , Edwards Joanne , Hayday Adrian , Sansom Owen J. , Coffelt Seth B.
Published: August 2023

Correlation between gut-specific transcription factors, gamma delta T cell density and BTNL genes in human tumors
Figure S2 from Circulating and Intratumoral Immune Determinants of Response to Atezolizumab plus Bevacizumab in Patients with Variant Histology or Sarcomatoid Renal Cell Carcinoma
Authors: Saliby Renee Maria , El Zarif Talal , Bakouny Ziad , Shah Valisha , Xie Wanling , Flippot Ronan , Denize Thomas , Kane M. Harry , Madsen Katrine N. , Ficial Miriam , Hirsch Laure , Wei Xiao X. , Steinharter John A. , Harshman Lauren C. , Vaishampayan Ulka N. , Severgnini Mariano , McDermott David F. , Lee Gwo-Shu Mary , Xu Wenxin , Van Allen Eliezer M. , McGregor Bradley A. , Signoretti Sabina , Choueiri Toni K. , McKay Rana R. , Braun David A.
Published: August 2023

Supplementary Figure 2
Figure S11 from Circulating and Intratumoral Immune Determinants of Response to Atezolizumab plus Bevacizumab in Patients with Variant Histology or Sarcomatoid Renal Cell Carcinoma
Authors: Saliby Renee Maria , El Zarif Talal , Bakouny Ziad , Shah Valisha , Xie Wanling , Flippot Ronan , Denize Thomas , Kane M. Harry , Madsen Katrine N. , Ficial Miriam , Hirsch Laure , Wei Xiao X. , Steinharter John A. , Harshman Lauren C. , Vaishampayan Ulka N. , Severgnini Mariano , McDermott David F. , Lee Gwo-Shu Mary , Xu Wenxin , Van Allen Eliezer M. , McGregor Bradley A. , Signoretti Sabina , Choueiri Toni K. , McKay Rana R. , Braun David A.
Published: August 2023

Supplementary Figure 11
Figure S10 from Circulating and Intratumoral Immune Determinants of Response to Atezolizumab plus Bevacizumab in Patients with Variant Histology or Sarcomatoid Renal Cell Carcinoma
Authors: Saliby Renee Maria , El Zarif Talal , Bakouny Ziad , Shah Valisha , Xie Wanling , Flippot Ronan , Denize Thomas , Kane M. Harry , Madsen Katrine N. , Ficial Miriam , Hirsch Laure , Wei Xiao X. , Steinharter John A. , Harshman Lauren C. , Vaishampayan Ulka N. , Severgnini Mariano , McDermott David F. , Lee Gwo-Shu Mary , Xu Wenxin , Van Allen Eliezer M. , McGregor Bradley A. , Signoretti Sabina , Choueiri Toni K. , McKay Rana R. , Braun David A.
Published: August 2023

Supplementary Figure 10
Figure S1 from Circulating and Intratumoral Immune Determinants of Response to Atezolizumab plus Bevacizumab in Patients with Variant Histology or Sarcomatoid Renal Cell Carcinoma
Authors: Saliby Renee Maria , El Zarif Talal , Bakouny Ziad , Shah Valisha , Xie Wanling , Flippot Ronan , Denize Thomas , Kane M. Harry , Madsen Katrine N. , Ficial Miriam , Hirsch Laure , Wei Xiao X. , Steinharter John A. , Harshman Lauren C. , Vaishampayan Ulka N. , Severgnini Mariano , McDermott David F. , Lee Gwo-Shu Mary , Xu Wenxin , Van Allen Eliezer M. , McGregor Bradley A. , Signoretti Sabina , Choueiri Toni K. , McKay Rana R. , Braun David A.
Published: August 2023

Supplementary Figure 1
Supplementary Data from T cell–Mediated Development of Stromal Fibroblasts with an Immune-Enhancing Chemokine Profile
Authors: Yan Ran , Moresco Philip , Gegenhuber Bruno , Fearon Douglas T.
Published: August 2023

Figure S1, S2, S3
Figure S3 from β-Catenin Drives Butyrophilin-like Molecule Loss and γδ T-cell Exclusion in Colon Cancer
Authors: Suzuki Toshiyasu , Kilbey Anna , Casa-Rodríguez Nuria , Lawlor Amy , Georgakopoulou Anastasia , Hayman Hannah , Yin Swe Kyi Lai , Nordin Anna , Cantù Claudio , Vantourout Pierre , Ridgway Rachel A. , Byrne Ryan M. , Chen Lei , Verzi Michael P. , Gay David M. , Gil Vázquez Ester , Belnoue-Davis Hayley L. , Gilroy Kathryn , Køstner Anne Helene , Kersten Christian , Thuwajit Chanitra , Andersen Ditte K. , Wiesheu Robert , Jandke Anett , Blyth Karen , Roseweir Antonia K. , Leedham Simon J. , Dunne Philip D. , Edwards Joanne , Hayday Adrian , Sansom Owen J. , Coffelt Seth B.
Published: August 2023

Knockdown of Cdx1, Cdx2 and Hnf4a fails to influence organoid morphology or expression of Btnl genes
Figure S2 from β-Catenin Drives Butyrophilin-like Molecule Loss and γδ T-cell Exclusion in Colon Cancer
Authors: Suzuki Toshiyasu , Kilbey Anna , Casa-Rodríguez Nuria , Lawlor Amy , Georgakopoulou Anastasia , Hayman Hannah , Yin Swe Kyi Lai , Nordin Anna , Cantù Claudio , Vantourout Pierre , Ridgway Rachel A. , Byrne Ryan M. , Chen Lei , Verzi Michael P. , Gay David M. , Gil Vázquez Ester , Belnoue-Davis Hayley L. , Gilroy Kathryn , Køstner Anne Helene , Kersten Christian , Thuwajit Chanitra , Andersen Ditte K. , Wiesheu Robert , Jandke Anett , Blyth Karen , Roseweir Antonia K. , Leedham Simon J. , Dunne Philip D. , Edwards Joanne , Hayday Adrian , Sansom Owen J. , Coffelt Seth B.
Published: August 2023

Deletion of Apc in organoids increases WNT target genes
Figure 7 from β-Catenin Drives Butyrophilin-like Molecule Loss and γδ T-cell Exclusion in Colon Cancer
Authors: Suzuki Toshiyasu , Kilbey Anna , Casa-Rodríguez Nuria , Lawlor Amy , Georgakopoulou Anastasia , Hayman Hannah , Yin Swe Kyi Lai , Nordin Anna , Cantù Claudio , Vantourout Pierre , Ridgway Rachel A. , Byrne Ryan M. , Chen Lei , Verzi Michael P. , Gay David M. , Gil Vázquez Ester , Belnoue-Davis Hayley L. , Gilroy Kathryn , Køstner Anne Helene , Kersten Christian , Thuwajit Chanitra , Andersen Ditte K. , Wiesheu Robert , Jandke Anett , Blyth Karen , Roseweir Antonia K. , Leedham Simon J. , Dunne Philip D. , Edwards Joanne , Hayday Adrian , Sansom Owen J. , Coffelt Seth B.
Published: August 2023

Inhibition of β-catenin transcriptional activity increases expression of HNF4A, HNF4G, and butyrophilin-like molecules. A, Vγ7+ cell viability in cocultures with CT26 or CT26-B1/6 cells. Each dot represents one paired biological replicate (n = 4). B, CD25 expression by Vγ7+ cells in cocultures with CT26 or CT26-B1/6 cells. Each dot represents one paired biological replicate (n = 4). C, CT26 and CT26-B1/6 cancer cell death using flow cytometry after coculture with Vγ7+ cell as indicated. Each dot represents one biological replicate (n = 4). D, Kaplan–Meier survival analysis of doxycycline-treated CT26 and CT26-B1/6 tumor-bearing mice (n = 4 CT26, 5 CT26-B1/6) using the log-rank test. E, γδ T-cell numbers in tumors from doxycycline-treated CT26 and CT26-B1/6 tumor-bearing mice. Each dot represents one mouse (n = 4 CT26, 5 CT26-B1/6). F and H, Images taken from serially stained sections of indicated protein in tumors from indicated mouse models (n = 3–4; scale bar, 500 μm. G and I, Images of Trdc expression in tumors from indicated mouse models; scale bar, 500 μm. γδ T-cell numbers in tumors. Each dot represents one mouse. Data are presented as mean ± SD. *, P < 0.05; **, P < 0.01 (paired t test or unpaired t test or one-way ANOVA followed by Tukey post hoc test).
Figure 6 from β-Catenin Drives Butyrophilin-like Molecule Loss and γδ T-cell Exclusion in Colon Cancer
Authors: Suzuki Toshiyasu , Kilbey Anna , Casa-Rodríguez Nuria , Lawlor Amy , Georgakopoulou Anastasia , Hayman Hannah , Yin Swe Kyi Lai , Nordin Anna , Cantù Claudio , Vantourout Pierre , Ridgway Rachel A. , Byrne Ryan M. , Chen Lei , Verzi Michael P. , Gay David M. , Gil Vázquez Ester , Belnoue-Davis Hayley L. , Gilroy Kathryn , Køstner Anne Helene , Kersten Christian , Thuwajit Chanitra , Andersen Ditte K. , Wiesheu Robert , Jandke Anett , Blyth Karen , Roseweir Antonia K. , Leedham Simon J. , Dunne Philip D. , Edwards Joanne , Hayday Adrian , Sansom Owen J. , Coffelt Seth B.
Published: August 2023

Activation of β-catenin decreases Hnf4a and Hnf4g expressions. A, Expressions of HNF4A and HNF4G in normal human colonic tissue and tumor tissue from TCGA (n = 19 normal, 101 tumor) and Skrypczak (n = 24 normal, 45 tumor) datasets. Data are presented as median ± minimum/maximum. *, P < 0.05 (Mann–Whitney U test). B,Hnf4a and Hnf4g expressions are determined by RNA-seq analysis of SI in WT (n = 9), VAF/F (n = 36), and VAF/FK (n = 17) mice. Each dot represents one mouse. C, Images of HNF4A and HNF4G protein expressions in SI of indicated models (n = 4); scale bar, 500 μm. D, Images of intestinal tissue from tumor-bearing VA mice stained for indicated proteins; scale bar, 500 μm. E, Fold change in expression levels of Hnf4a and Hnf4g in organoids from various genotypes measured at indicated days after tamoxifen treatment. Each dot represents one organoid from one mouse (n = 3). F, Fold change in expression levels of Hnf4a and Hnf4g in WT organoids treated with 3 or 10 μmol/L CHIR-99021 for indicated days. Each dot represents one organoid from one mouse (n = 3). Data are presented as mean ± SD. **, P < 0.01; ***, P < 0.001 (one-way ANOVA followed by Dunnett post hoc test).
Figure 3 from β-Catenin Drives Butyrophilin-like Molecule Loss and γδ T-cell Exclusion in Colon Cancer
Authors: Suzuki Toshiyasu , Kilbey Anna , Casa-Rodríguez Nuria , Lawlor Amy , Georgakopoulou Anastasia , Hayman Hannah , Yin Swe Kyi Lai , Nordin Anna , Cantù Claudio , Vantourout Pierre , Ridgway Rachel A. , Byrne Ryan M. , Chen Lei , Verzi Michael P. , Gay David M. , Gil Vázquez Ester , Belnoue-Davis Hayley L. , Gilroy Kathryn , Køstner Anne Helene , Kersten Christian , Thuwajit Chanitra , Andersen Ditte K. , Wiesheu Robert , Jandke Anett , Blyth Karen , Roseweir Antonia K. , Leedham Simon J. , Dunne Philip D. , Edwards Joanne , Hayday Adrian , Sansom Owen J. , Coffelt Seth B.
Published: August 2023

Expression of butyrophilin-like molecules is reduced in gut tumors. A, Images of intestinal tissue from indicated models (n = 4) stained for Btnl1 mRNA. T, tumor; scale bar, 100 μm. B, Images of intestinal tissue from indicated models (n = 4) stained for Btnl1 mRNA; scale bar, 100 μm. C, Butyrophilin-like mRNA expression shown by bar graph generated from RNA-seq data from WT (n = 9), VAF/F (n = 36), and VAF/FK (n = 17) mice. Data are presented as mean ± SD. D, Expressions of BTNL3 and BTNL8 in normal human colonic tissue and tumor tissue from TCGA (n = 19 normal, 101 tumor; ref. 9) and Skrypczak (n = 24 normal, 45 tumor; ref. 27) datasets. Data are presented as median ± min/max. E–G, Correlation between indicated molecules as determined by TempO-Seq and γδ T-cell density determined by IHC in the Scotland cohort from 77 matched pairs. Units on axes are normalized read counts x 103. Each dot represents one tumor. P and r values determined by Pearson correlation. *, P < 0.05; **, P < 0.01; ***, P < 0.001 (Mann–Whitney U test or one-way ANOVA followed by Tukey post hoc test).
Figure 2 from β-Catenin Drives Butyrophilin-like Molecule Loss and γδ T-cell Exclusion in Colon Cancer
Authors: Suzuki Toshiyasu , Kilbey Anna , Casa-Rodríguez Nuria , Lawlor Amy , Georgakopoulou Anastasia , Hayman Hannah , Yin Swe Kyi Lai , Nordin Anna , Cantù Claudio , Vantourout Pierre , Ridgway Rachel A. , Byrne Ryan M. , Chen Lei , Verzi Michael P. , Gay David M. , Gil Vázquez Ester , Belnoue-Davis Hayley L. , Gilroy Kathryn , Køstner Anne Helene , Kersten Christian , Thuwajit Chanitra , Andersen Ditte K. , Wiesheu Robert , Jandke Anett , Blyth Karen , Roseweir Antonia K. , Leedham Simon J. , Dunne Philip D. , Edwards Joanne , Hayday Adrian , Sansom Owen J. , Coffelt Seth B.
Published: August 2023

γδ T cells are excluded from mouse and human gut tumors. A, Images of SI tissue from 4 WT (Cre-negative), tumor-bearing Villin-CreERT2;ApcF/+ (VA) and tumor-bearing Villin-CreERT2;ApcF/+;KrasG12D (VAK) mice stained for Trdc mRNA; scale bar, 500 μm. B, γδ T-cell numbers in SI tissue of indicated models. Each dot represents one mouse (n = 11 WT, 3 VA, 3 VAK). C, Representative flow cytometry plot of CD8α and γδTCR expressions on total CD3+ cells in the small intestine of WT mice. CD8α+ γδ T-cell frequency in SI of indicated models. Each dot represents one mouse (n = 9 WT, 4 VA, 5 VAK). D, Images of SI from indicated models (n = 4/group) stained for Trdc mRNA; scale bar, 500 μm. E, γδ T-cell numbers in SI of indicated models. Each dot represents one mouse (n = 3 WT, 4 VAF/F, 4 VAF/FK). F, Image of γδ T-cell staining in tumor adjacent tissue and tumor tissue from human colon cancer sections (Scotland cohort, n = 141) where arrows indicate positively stained cells; scale bar, 500 μm. G, Density of γδ T cells in human colon cancer sections in three different patient cohorts: Scotland (n = 141), Norway (n = 71), and Thailand (n = 122). γδ T cells identified by IHC in full sections were quantified in tumor adjacent tissue or tumor tissue using Visiopharm. Data are presented as median ± min/max. H, Expressions of TRGV4 and TRGV9 mRNA in human colon cancer samples (n = 82) from the Scotland cohort determined by TempO-Seq. Data are presented as mean ± SD. *, P < 0.05; **, P < 0.01; ***, P < 0.001 (paired t test or one-way ANOVA followed by Dunnett post hoc test).
Figure 1 from β-Catenin Drives Butyrophilin-like Molecule Loss and γδ T-cell Exclusion in Colon Cancer
Authors: Suzuki Toshiyasu , Kilbey Anna , Casa-Rodríguez Nuria , Lawlor Amy , Georgakopoulou Anastasia , Hayman Hannah , Yin Swe Kyi Lai , Nordin Anna , Cantù Claudio , Vantourout Pierre , Ridgway Rachel A. , Byrne Ryan M. , Chen Lei , Verzi Michael P. , Gay David M. , Gil Vázquez Ester , Belnoue-Davis Hayley L. , Gilroy Kathryn , Køstner Anne Helene , Kersten Christian , Thuwajit Chanitra , Andersen Ditte K. , Wiesheu Robert , Jandke Anett , Blyth Karen , Roseweir Antonia K. , Leedham Simon J. , Dunne Philip D. , Edwards Joanne , Hayday Adrian , Sansom Owen J. , Coffelt Seth B.
Published: August 2023

Loss of Btnl1 increases adenoma formation in Apc-deficient mouse models. A, Images of SI from VA and VA;Btnl1—/— mice stained for Btnl1 mRNA representative of 4/group; scale bar, 100 μm. B, Images of SI from VA and VA;Btnl1—/— mice stained for Trdc mRNA; scale bar, 500 μm. γδ T-cell numbers in SI of indicated models. Each dot represents one mouse (n = 3). C, Kaplan–Meier survival analysis of VA (n = 15) and VA;Btnl1—/— (n = 6) mice. D, Tumor number and tumor burden (mm2) in SI and colon of VA and VA;Btnl1—/— mice. Each dot represents one mouse (n = 15 VA, 6 VA;Btnl1—/— mice). Data are presented as mean ± SD. *, P < 0.05; ***, P < 0.001 (unpaired t test).
Supplementary Data T4 from A Survey of Cancer Risk Behaviors, Beliefs, and Social Drivers of Health in New Hampshire and Vermont
Authors: Skipper Thomas A , Weiss Julie E , Carlos Heather A , Gunn Christine M , Hasson Rian M , Peacock Janet L , Schiffelbein Jenna E , Tosteson Anna N.A. , Lansigan Frederick , Rees Judy R
Published: August 2023

Cancer beliefs by rurality and educational attainment
Supplementary Data T3 from A Survey of Cancer Risk Behaviors, Beliefs, and Social Drivers of Health in New Hampshire and Vermont
Authors: Skipper Thomas A , Weiss Julie E , Carlos Heather A , Gunn Christine M , Hasson Rian M , Peacock Janet L , Schiffelbein Jenna E , Tosteson Anna N.A. , Lansigan Frederick , Rees Judy R
Published: August 2023

Cancer risk and prevention behaviors by rurality and educational attainment
Supplementary Data T2 from A Survey of Cancer Risk Behaviors, Beliefs, and Social Drivers of Health in New Hampshire and Vermont
Authors: Skipper Thomas A , Weiss Julie E , Carlos Heather A , Gunn Christine M , Hasson Rian M , Peacock Janet L , Schiffelbein Jenna E , Tosteson Anna N.A. , Lansigan Frederick , Rees Judy R
Published: August 2023

Comparison of key variables between responders and non responders
Supplementary Data T1 from A Survey of Cancer Risk Behaviors, Beliefs, and Social Drivers of Health in New Hampshire and Vermont
Authors: Skipper Thomas A , Weiss Julie E , Carlos Heather A , Gunn Christine M , Hasson Rian M , Peacock Janet L , Schiffelbein Jenna E , Tosteson Anna N.A. , Lansigan Frederick , Rees Judy R
Published: August 2023

Survey instrument
Supplemental Table S5 from Tusamitamab ravtansine in patients with advanced solid tumors: Phase 1 study of safety, pharmacokinetics, and antitumor activity using alternative dosing regimens
Authors: Tabernero Josep , Bedard Philippe L. , Bang Yung-Jue , Vieito Maria , Ryu Min-Hee , Fagniez Nathalie , Chadjaa Mustapha , Soufflet Christine , Masson Nina , Gazzah Anas
Published: August 2023

Plasma pharmacokinetics of tusamitamab ravtansine (cohort Q3W)
Supplemental Table S2 from Tusamitamab ravtansine in patients with advanced solid tumors: Phase 1 study of safety, pharmacokinetics, and antitumor activity using alternative dosing regimens
Authors: Tabernero Josep , Bedard Philippe L. , Bang Yung-Jue , Vieito Maria , Ryu Min-Hee , Fagniez Nathalie , Chadjaa Mustapha , Soufflet Christine , Masson Nina , Gazzah Anas
Published: August 2023

Representativeness of the patient population
Data from A Survey of Cancer Risk Behaviors, Beliefs, and Social Drivers of Health in New Hampshire and Vermont
Authors: Skipper Thomas A. , Weiss Julie E. , Carlos Heather A. , Gunn Christine M. , Hasson Rian M. , Peacock Janet L. , Schiffelbein Jenna E. , Tosteson Anna N.A. , Lansigan Frederick , Rees Judy R.
Published: August 2023

Compared with urban areas, rural areas have higher cancer mortality and have experienced substantially smaller declines in cancer incidence in recent years. In a New Hampshire (NH) and Vermont (VT) survey, we explored the roles of rurality and educational attainment on cancer risk behaviors, beliefs, and other social drivers of health. In February–March 2022, two survey panels in NH and VT were sent an online questionnaire. Responses were analyzed by rurality and educational attainment. Respondents (N = 1,717, 22%) mostly lived in rural areas (55%); 45% of rural and 25% of urban residents had high school education or less and this difference was statistically significant. After adjustment for rurality, lower educational attainment was associated with smoking, difficulty paying for basic necessities, greater financial difficulty during the COVID-19 pandemic, struggling to pay for gas (P < 0.01), fatalistic attitudes toward cancer prevention, and susceptibility to information overload about cancer prevention. Among the 33% of respondents who delayed getting medical care in the past year, this was more often due to lack of transportation in those with lower educational attainment (21% vs. 3%, P = 0.02 adjusted for rurality) and more often due to concerns about catching COVID-19 among urban than rural residents (52% vs. 21%; P < 0.001 adjusted for education). In conclusion, in NH/VT, smoking, financial hardship, and beliefs about cancer prevention are independently associated with lower educational attainment but not rural residence. These findings have implications for the design of interventions to address cancer risk in rural areas.
Significance:
In NH and VT, the finding that some associations between cancer risk factors and rural residence are more closely tied to educational attainment than rurality suggest that the design of interventions to address cancer risk should take educational attainment into account.
Adjustable Continence Therapy Balloons in Female Patients with Stress Urinary Incontinence: A Systematic Review
Authors: Guérin Sonia , Khene Zine-Eddine , Peyronnet Benoit
Published: August 2023

Introduction: The aim of this study was to perform a systematic review of studies reporting the outcomes of ACT® balloons in female patients with stress urinary incontinence (SUI) due to intrinsic sphincter deficiency (ISD). Methods: In accordance with PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analysis) standards, a systematic search of the PubMed (Medline) and Scopus electronic database was performed in June 2022. Terms used for the query were (“female” or “women”) and (“adjustable continence therapy” OR “periurethral balloons”). Results: Thirteen studies were included. All were retrospective or prospective case series. The success rates ranged from 13.6% to 68% and the improvement rates from 16% to 83%. The intraoperative complication rate ranged from 3.5 to 25% and consisted of urethral, bladder, or vaginal perforations. The rate of postoperative complications varied from 11 to 56% without major complications. Between 6% and 38% of ACT® balloons were explanted and subsequently reimplanted in 15.2–63% of cases. Conclusion: ACT® balloons can be considered as an option to treat SUI due to ISD in female patients with a relatively modest success rate and quite a high complication rate. Well-designed prospective studies and long-term follow-up data are needed to fully elucidate their role.
Deep Brain Stimulation for Chronic Cluster Headaches: A Systematic Review and Meta-Analysis
Authors: Murray Molly , Pahapill Peter A , Awad Ahmed J
Published: August 2023

Background: Chronic cluster headache (CCH) is a severe and debilitating sub-type of trigeminal autonomic cephalalgia that can be resistant to medical management and associated with significant impairment in quality of life. Studies of deep brain stimulation (DBS) for CCH have provided promising results but have not been assessed in a comprehensive systematic review/meta-analysis. Objective: The objective was to perform a systematic literature review and meta-analysis of patients with CCH treated with DBS to provide insight on safety and efficacy. Methods: A systematic review and meta-analysis were performed according to PRISMA 2020 guidelines. 16 studies were included in final analysis. A random-effects model was used to meta-analyze data. Results: Sixteen studies reported 108 cases for data extraction and analysis. DBS was feasible in >99% of cases and was performed either awake or asleep. Meta-analysis revealed that the mean difference in headache attack frequency and headache intensity after DBS were statistically significant (p < 0.0001). Utilization of microelectrode recording was associated with statistically significant improvement in headache intensity postoperatively (p = 0.006). The average overall follow-up period was 45.4 months and ranged from 1 to 144 months. Death occurred in <1%. The rate of major complications was 16.67%. Conclusions: DBS for CCHs is a feasible surgical technique with a reasonable safety profile that can be successfully performed either awake or asleep. In carefully selected patients, approximately 70% of patients achieve excellent control of their headaches.
Allergic Fungal Rhinosinusitis in Europe: Literature Review and Own Experience
Authors: Kokoszka Magdalena , Stryjewska-Makuch Grażyna , Kantczak Ada , Górny Dorota , Glück Joanna
Published: August 2023

Allergic fungal rhinosinusitis (AFRS) is primary, Th2-mediated, chronic rhinosinusitis, which is diagnosed when the criteria defined by Bent and Khun are met. The disease is most common in countries located in the subtropical and tropical regions characterized by high temperatures and high levels of humidity, which favour the wider occurrence of fungi in the environment. The presence of specific IgE antibodies directed against fungal allergens, which is one of the diagnostic criteria, proves the systemic nature of the disease and allows one to distinguish AFRS from eosinophilic fungal rhinosinusitis. There is no unified treatment method for AFRS described in the literature, and relapses are common. Sinus surgery remains the treatment of choice. Oral and topical steroid therapy plays an important role in the treatment process. The effectiveness of antifungal treatment and immunotherapy is unclear. Biological treatment, the results of which are promising, has raised great hopes. The aim of this study was to reveal how often AFRS occurs in European countries, what environmental factors influence its development, and how important it is to specify its diagnostic criteria and treatment methods. We present an overview of the available literature. In addition, we share our own experience and describe two cases of AFRS diagnosed and treated at our centre.
Comparative study of single precision floating point division using different computational algorithms
Authors: Singh Naginder , Parihar Kapil
Published: August 2023

This paper presents different computational algorithms to implement single precision floating point division on field programmable gate arrays (FPGA). Fast division computation algorithms can apply to all division cases by which an efficient result will be obtained in terms of delay time and power consumption. 24-bit Vedic multiplication (Urdhva-Triyakbhyam-sutra) technique enhances the computational speed of the mantissa module and this module is used to design a 32-bit floating point multiplier which is the crucial feature of this proposed design, which yields a higher computational speed and reduced delay time. The proposed design of floating-point divider using fast computational algorithms synthesized using Verilog hardware description language has a 32-bit floating point multiplier module unit and a 32-bit floating point subtractor module unit. Xilinx Spartan 6 SP605 evaluation platform is used to verify this proposed design on FPGA. Synthesis results provide the device utilization and propagation delay parameters for the proposed design and a comparative study is done with previous work. Input to the divider is provided in IEEE 754 32-bit formats.
Balancing of four wire loads using linearized H-bridge static synchronous compensators
Authors: Obais Abdulkareem Mokif , Mukheef Ali Abdulkareem
Published: August 2023

In this paper, a load balancing system is designed to balance the secondary phase currents of 11 kV/380 V, 50 Hz, 100 kVA power transformer in a three phase 4-wire, distribution network. The load balancing system is built of six identical modified static synchronous compensators (M-STATCOMs). Each M-STATCOM is constructed of a voltage source converter-based H-bridge controlled in capacitive and inductive modes as a linear compensating susceptance. The M-STATCOM current is controlled by varying its angle such that it exchanges pure reactive current with the utility grid. Three identical M-STATCOMs are connected in delta-form to balance the active phase currents of the power transformer, whereas the other three identical M-STATCOMs are connected in star-form to compensate for reactive currents. The M-STATCOMs in the delta-connected compensator are driven by 380 V line-to-line voltages, whilst, those connected in star-form are driven by 220 V phase voltages. The results of the 220 V and 380 V M-STATCOMs have exhibited linear and continuous control in capacitive and inductive regions of operation without steady-state harmonics. The proposed load balancing system has offered high flexibility during treating moderate and severe load unbalance conditions. It can involve any load unbalance within the power transformer current rating and even unbalance cases beyond the power transformer current rating.